Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Hansson, Emma C
MetadataShow full item record
CitationRecombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection. 2017, 154 (6):1852-1859.e2 J. Thorac. Cardiovasc. Surg.
AbstractSurgery for acute type A aortic dissection (ATAAD) is often complicated by excessive bleeding. Recombinant factor VIIa (rFVIIa) effectively treats refractory bleeding associated with ATAAD surgery; however, adverse effects of rFVIIa in these patients have not been fully assessed. Here we evaluated rFVIIa treatment in ATAAD surgery using the Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) database.
This was a multicenter, propensity score-matched, retrospective study. Information about rFVIIa use was available for 761 patients, of whom 171 were treated with rFVIIa. We successfully matched 120 patients treated with rFVIIa with 120 controls. Primary endpoints were in-hospital mortality, postoperative stroke, and renal replacement therapy (RRT). Survival data were presented using Kaplan-Meier estimates.
Compared with controls, patients treated with rFVIIa received more transfusions of packed red blood cells (median, 9.0 U [4.0-17.0 U] vs 5.0 U [2.0-11.0 U]; P = .008), platelets (4.0 U [2.0-8.0 U] vs 2.0 U [1.0-4.4 U]; P <.001), and fresh frozen plasma (8.0 U [4.0-18.0 U] vs 5.5 U [2.0-10.3 U]; P = .01) underwent reexploration for bleeding more often (31.0% vs 16.8%; P = .014); and had greater 24-hour chest tube output (1500 L [835-2500 mL] vs 990 mL [520-1720 mL]). Treatment with rFVIIa was not associated with significantly increased rates of in-hospital mortality (odds ratio [OR], 0.74; 95% confidence interval [CI], 0.34-1.55; P = .487), postoperative stroke (OR, 1.75; 95% CI, 0.82-3.91; P = .163), or RRT (OR, 1.18; 95% CI, 0.48-2.92; P = .839).
In this propensity-matched cohort study of patients undergoing ATAAD surgery, treatment with rFVIIa for major bleeding was not associated with a significantly increased risk of stroke, RRT, or mortality.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
RightsArchived with thanks to The Journal of thoracic and cardiovascular surgery
- Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis.
- Authors: Tritapepe L, De Santis V, Vitale D, Nencini C, Pellegrini F, Landoni G, Toscano F, Miraldi F, Pietropaoli P
- Issue date: 2007 Jul
- Recombinant activated factor VII for treatment of refractory hemorrhage after surgery for acute aortic dissection.
- Authors: Grubitzsch H, Vargas-Hein O, Von Heymann C, Konertz W
- Issue date: 2009 Aug
- Malperfusion in acute type A aortic dissection: An update from the Nordic Consortium for Acute Type A Aortic Dissection.
- Authors: Zindovic I, Gudbjartsson T, Ahlsson A, Fuglsang S, Gunn J, Hansson EC, Hjortdal V, Järvelä K, Jeppsson A, Mennander A, Olsson C, Pan E, Sjögren J, Wickbom A, Geirsson A, Nozohoor S
- Issue date: 2019 Apr
- Intraoperative use of recombinant activated factor VII during complex aortic surgery.
- Authors: Goksedef D, Panagopoulos G, Nassiri N, Levine RL, Hountis PG, Plestis KA
- Issue date: 2012 May
- The Nordic Consortium for Acute type A Aortic Dissection (NORCAAD): objectives and design<sup/>.
- Authors: Geirsson A, Ahlsson A, Franco-Cereceda A, Fuglsang S, Gunn J, Hansson EC, Hjortdal V, Jarvela K, Jeppsson A, Mennander A, Nozohoor S, Olsson C, Wickbom A, Zindovic I, Gudbjartsson T
- Issue date: 2016 Oct - Dec